Trial · NCT04965532
Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia
NCT04965532, Not applicable, Unknown, Second Affiliated Hospital, Zhejiang University, School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia. Trials, record NCT04965532. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04965532
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia
- NCT number
- NCT04965532
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Conditions
- Chemotherapeutic Toxicity
- Interventions
- sevoflurane anesthesia, Propofol Injection
- First posted
- 2021-07-16
- Last updated
- 2021-07-16
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Muscle relaxation recovery index | The first 90 min following intravenous injection of rocuronium | Time interval from 25% recovery to 75% recovery of the first twitch in the TOF stimulation pattern |
| Secondary | Onset time of muscle relaxation | The first 90 min following intravenous injection of rocuronium | Time interval from the completion of intravenous injection of rocuronium to the maximal depression of the first twitch in the TOF stimulation pattern |
| Other | Clinical duration of muscle relaxation | The first 90min following intravenous injection of rocuronium | Time interval from the completion of intravenous injection of rocuronium to 25% recovery of the first twitch in the TOF stimulation pattern |
| Other | TOF ratio | 10min following intravenous injection of rocuronium | Dividing the amplitude of the fourth response by the amplitude of the first response |
| Other | T1 amplitude | 10min following intravenous injection of rocuronium | The amplitude of the first twitch to TOF stimulation |
| Other | TOF ratio | 20min following intravenous injection of rocuronium | Dividing the amplitude of the fourth response by the amplitude of the first response |
| Other | T1 amplitude | 20min following intravenous injection of rocuronium | The amplitude of the first twitch to TOF stimulation |
| Other | TOF ratio | 30min following intravenous injection of rocuronium | Dividing the amplitude of the fourth response by the amplitude of the first response |
| Other | T1 amplitude | 30min following intravenous injection of rocuronium | The amplitude of the first twitch to TOF stimulation |
| Other | TOF ratio | 40min following intravenous injection of rocuronium | Dividing the amplitude of the fourth response by the amplitude of the first response |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04965532
GET https://conductscience.org/api/trials/v1/NCT04965532/registered?page=2